Corrigendum to "PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor" [Volume 14, Issue 9, September 2021, 101152].
Transl Oncol
; 17: 101344, 2022 Mar.
Article
in En
| MEDLINE
| ID: mdl-35042060
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Transl Oncol
Year:
2022
Document type:
Article
Affiliation country:
Japan
Country of publication:
United States